Jason A Duquette

This inventor holds 21 USPTO granted patents and 11 published patent applications, plus 5 CIPO patents and 12 EPO patents, primarily in Heterocyclic Compounds. Top assignees: Amgen Inc., Epiodyne, Inc., Amgen Sf, LLC. Active years: 2007-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jason A Duquette. Retrieved from https://idiyas.com/inventor/jason-a-duquette

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 11)

% Patents Active = 66.7

CIPO Patents = 5 (Patent Applications = 4)

EPO Patents = 12 (Patent Applications = 11)

Average Co-Inventor Count = 12.7

ph-index = 7

Forward Citations = 126(Granted Patents)

Location History:

San Mateo, CA (US) (2007 - 2012)
South San Francisco, CA (US) (2014 - 2016)
Milbrae, CA (US) (2018)
Union City, CA (US) (2022)
Millbrae, CA (US) (2008 - 2023)

Company Filing History:

Bayer Intellectual Property Gmbh

patents

5. 1 out of 192

Bayer Schering Pharma Ag

patents

Years Active: 2007-2024

Loading Chart...

Areas of Expertise:

Opioid Receptor Modulators

Heterocyclic Compounds

MDM2 Inhibitors

Cancer Treatment

CDK 4/6 Inhibitors

FLT3 Inhibitors

Hyperproliferative Disorders

Inflammatory Disorders

Immunoregulatory Disorders

Piperidinone Derivatives

Aryl Nitrile Compounds

Fused Tricyclic Compounds

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12168648 - Opioid receptor modulators (2024-12-17),

2. 11634396 - Opioid receptor modulators (2023-04-25),

3. 11352316 - Opioid receptor modulators and products and methods related thereto (2022-06-07),

4. 11306107 - Compounds that inhibit MCL-1 protein (2022-04-19),

5. 9873704 - Heterocyclic compounds and their uses (2018-01-23),

6. 9873701 - Heterocyclic compounds and their uses (2018-01-23),

7. 9593129 - Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer (2017-03-14),

8. 9376425 - Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer (2016-06-28),

9. 9359355 - Fused tricyclic dual inhibitors of CDK 4/6 and FLT3 (2016-06-07),

10. 9296736 - Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer (2016-03-29),

11. 8901135 - Heterocyclic compounds and their uses (2014-12-02),

12. 8623885 - Fused tricyclic dual inhibitors of CDK 4/6 and FLT3 (2014-01-07),

13. 8586739 - Heterocyclic compounds and their uses (2013-11-19),

14. 8575183 - Heterocyclic compounds and their uses (2013-11-05),

15. 8207172 - Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders (2012-06-26),

Hello! I'd be happy to assist with the article about inventor Jason A Duquette.

Title: Exploring the Innovations of Jason A Duquette from Millbrae, CA

Introduction:

Jason A Duquette, a prolific inventor based in Millbrae, CA, has made significant contributions to the field of pharmaceuticals with his groundbreaking patents.

Latest Patents:

Duquette's recent patents include "Opioid receptor modulators" and "Opioid receptor modulators and products and methods related thereto." These patents showcase his expertise in developing compounds that modulate opioid receptors, particularly the mu-opioid receptor (MOR) and/or the kappa-opioid receptor (KOR), among others.

Career Highlights:

Currently affiliated with Amgen SF, LLC, Duquette has accumulated an impressive portfolio of 20 patents throughout his career. His work reflects a dedication to advancing the field of pharmaceuticals with innovative solutions.

Collaborations:

Duquette has collaborated with notable individuals in his field, including coworkers such as Julio Cesar Medina and Xiaoqi Chen. These collaborations have further enriched his research and development efforts.

Conclusion:

In conclusion, Jason A Duquette stands out as a talented inventor whose patents in opioid receptor modulation pave the way for novel pharmaceutical compositions. His relentless pursuit of innovation and collaborations underscore his commitment to driving progress in the industry.

Profile summary based on public USPTO records.